Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe

Nienke Bruinsma; Karl G. Kristinsson; Stef Bronzwaer; Paul Schrijnemakers; John Degener; Edine Tiemersma; Waleria Hryniewicz; Jos Monen; Hajo Grundmann; H. Mittermayer; W. Koller; H. Goossens; E. Hendrickx; B. Markova; S. Kalenic; A. Tambic-Andrasevic; P. Urbaskova; D. Monnet; P. Naaber; O. Lyytikäinen; A. Nissinen; H. Aubry-Damon; P. Courvalin; U. Buchholz; W. Witte; N. Legakis; G. Vatopoulos; M. Füzi; D. O'Flanagan; O. Murphy; R. Raz; H. Edelstein; G. Cornaglia; P. D'Ancona; R. Hemmer; M. Borg; A. de Neeling; A. Hoiby; E. Bjørløw; M. Caniça; I. Codita; M. Gubina; J. Kolman; L. Langsadl; F. Baquero; J. Campos; B. Liljequist; A. Johnson; M. Wale

doi:10.1093/jac/dkh458

Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe

Nienke Bruinsma^*, Karl G. Kristinsson, Stef Bronzwaer, Paul Schrijnemakers, John Degener, Edine Tiemersma, Waleria Hryniewicz, Jos Monen, Hajo Grundmann, H. Mittermayer, W. Koller, H. Goossens, E. Hendrickx, B. Markova, S. Kalenic, A. Tambic-Andrasevic, P. Urbaskova, D. Monnet, P. Naaber, O. LyytikäinenA. Nissinen, H. Aubry-Damon, P. Courvalin, U. Buchholz, W. Witte, N. Legakis, G. Vatopoulos, M. Füzi, D. O'Flanagan, O. Murphy, R. Raz, H. Edelstein, G. Cornaglia, P. D'Ancona, R. Hemmer, M. Borg, A. de Neeling, A. Hoiby, E. Bjørløw, M. Caniça, I. Codita, M. Gubina, J. Kolman, L. Langsadl, F. Baquero, J. Campos, B. Liljequist, A. Johnson, M. Wale

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

Objectives: To forecast trends in resistance to penicillin and erythromycin among Streptococcus pneumoniae in Europe. Methods: Since 1999, the European Antimicrobial Resistance Surveillance System (EARSS) has collected routine antimicrobial susceptibility test results of S. pneumoniae. To observe and predict changes of reduced susceptibility over time, we used a multinomial logistic regression model. Results: Large variations in penicillin and erythromycin non-susceptibility were observed between countries, and reduced susceptibility to erythromycin (17%) has become more frequent than reduced susceptibility to penicillin (10%) in Europe overall. An overall decrease in single penicillin non-susceptibility, but an increase in dual non-susceptibility was observed, indicating a shift of single penicillin to combined non-susceptibility with erythromycin. By 2006, the proportion of single erythromycin and dual non-susceptibility could increase to as much as 20.4% and 8.9%, respectively. Conclusions: Our results indicate that appropriately dosed β-lactams for empirical therapy are still the treatment of choice, and that macrolides should be used with prudence.

Original language	English
Pages (from-to)	1045-1050
Number of pages	6
Journal	Journal of Antimicrobial Chemotherapy
Volume	54
Issue number	6
DOIs	https://doi.org/10.1093/jac/dkh458
Publication status	Published - Dec 2004
Externally published	Yes

Bibliographical note

Funding Information:
We gratefully thank all national representatives, data managers and the EARSS advisory board for contributing to the success of the network during the past 5 years. We are indebted to all EARSS participants for allowing us to use their data for the present study. The EARSS national representatives for 2002 were H. Mittermayer, W. Koller (Austria), H. Goossens, E. Hendrickx (Belgium), B. Markova (Bulgaria), S. Kalenic, A. Tambic-Andrasevic (Croatia), P. Urbaskova (Czech Republic), D. Monnet (Denmark), P. Naaber (Estonia), O. Lyytikäinen, A. Nissinen (Finland), H. Aubry-Damon, P. Courvalin (France), U. Buchholz, W. Witte (Germany), N. Legakis, G. Vatopoulos (Greece), M. Füzi (Hungary), K. Kristinsson (Iceland), D. O’Flanagan, O. Murphy (Ireland), R. Raz, H. Edelstein (Israel), G. Cornaglia, P. D’Ancona (Italy), R. Hemmer (Luxembourg), M. Borg (Malta), A. de Neeling, E. Tiemersma (The Netherlands), A. Hoiby, E. Bjørløw (Norway), W. Hryniewicz (Poland), M. Canic¸a (Portugal), I. Codita (Romania), M. Gubina, J. Kolman (Slovenia), L. Langsadl (Slovakia), F. Baquero, J. Campos (Spain), B. Liljequist (Sweden), A. Johnson, M. Wale (UK). We thank John Stelling for designing and maintaining the WHONET data-entering program, which is used by many EARSS participants. We thank Dr Nico Nagelkerke for his statistical advice. The EARSS is funded by the European Commission under SI2.324194 (2001CVG4-011) and the Dutch Ministry of Health, Welfare and Sports. This work was performed at the National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Keywords

Antimacrobial use
Antimicrobial resistance
Public health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkh458

Cite this

Bruinsma, N., Kristinsson, K. G., Bronzwaer, S., Schrijnemakers, P., Degener, J., Tiemersma, E., Hryniewicz, W., Monen, J., Grundmann, H., Mittermayer, H., Koller, W., Goossens, H., Hendrickx, E., Markova, B., Kalenic, S., Tambic-Andrasevic, A., Urbaskova, P., Monnet, D., Naaber, P., ... Wale, M. (2004). Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. Journal of Antimicrobial Chemotherapy, 54(6), 1045-1050. https://doi.org/10.1093/jac/dkh458

@article{eab48545c1e54179a298b0a3eb2396a6,

title = "Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe",

abstract = "Objectives: To forecast trends in resistance to penicillin and erythromycin among Streptococcus pneumoniae in Europe. Methods: Since 1999, the European Antimicrobial Resistance Surveillance System (EARSS) has collected routine antimicrobial susceptibility test results of S. pneumoniae. To observe and predict changes of reduced susceptibility over time, we used a multinomial logistic regression model. Results: Large variations in penicillin and erythromycin non-susceptibility were observed between countries, and reduced susceptibility to erythromycin (17%) has become more frequent than reduced susceptibility to penicillin (10%) in Europe overall. An overall decrease in single penicillin non-susceptibility, but an increase in dual non-susceptibility was observed, indicating a shift of single penicillin to combined non-susceptibility with erythromycin. By 2006, the proportion of single erythromycin and dual non-susceptibility could increase to as much as 20.4% and 8.9%, respectively. Conclusions: Our results indicate that appropriately dosed β-lactams for empirical therapy are still the treatment of choice, and that macrolides should be used with prudence.",

keywords = "Antimacrobial use, Antimicrobial resistance, Public health",

author = "Nienke Bruinsma and Kristinsson, {Karl G.} and Stef Bronzwaer and Paul Schrijnemakers and John Degener and Edine Tiemersma and Waleria Hryniewicz and Jos Monen and Hajo Grundmann and H. Mittermayer and W. Koller and H. Goossens and E. Hendrickx and B. Markova and S. Kalenic and A. Tambic-Andrasevic and P. Urbaskova and D. Monnet and P. Naaber and O. Lyytik{\"a}inen and A. Nissinen and H. Aubry-Damon and P. Courvalin and U. Buchholz and W. Witte and N. Legakis and G. Vatopoulos and M. F{\"u}zi and D. O'Flanagan and O. Murphy and R. Raz and H. Edelstein and G. Cornaglia and P. D'Ancona and R. Hemmer and M. Borg and {de Neeling}, A. and A. Hoiby and E. Bj{\o}rl{\o}w and M. Cani{\c c}a and I. Codita and M. Gubina and J. Kolman and L. Langsadl and F. Baquero and J. Campos and B. Liljequist and A. Johnson and M. Wale",

note = "Funding Information: We gratefully thank all national representatives, data managers and the EARSS advisory board for contributing to the success of the network during the past 5 years. We are indebted to all EARSS participants for allowing us to use their data for the present study. The EARSS national representatives for 2002 were H. Mittermayer, W. Koller (Austria), H. Goossens, E. Hendrickx (Belgium), B. Markova (Bulgaria), S. Kalenic, A. Tambic-Andrasevic (Croatia), P. Urbaskova (Czech Republic), D. Monnet (Denmark), P. Naaber (Estonia), O. Lyytik{\"a}inen, A. Nissinen (Finland), H. Aubry-Damon, P. Courvalin (France), U. Buchholz, W. Witte (Germany), N. Legakis, G. Vatopoulos (Greece), M. F{\"u}zi (Hungary), K. Kristinsson (Iceland), D. O{\textquoteright}Flanagan, O. Murphy (Ireland), R. Raz, H. Edelstein (Israel), G. Cornaglia, P. D{\textquoteright}Ancona (Italy), R. Hemmer (Luxembourg), M. Borg (Malta), A. de Neeling, E. Tiemersma (The Netherlands), A. Hoiby, E. Bj{\o}rl{\o}w (Norway), W. Hryniewicz (Poland), M. Canic¸a (Portugal), I. Codita (Romania), M. Gubina, J. Kolman (Slovenia), L. Langsadl (Slovakia), F. Baquero, J. Campos (Spain), B. Liljequist (Sweden), A. Johnson, M. Wale (UK). We thank John Stelling for designing and maintaining the WHONET data-entering program, which is used by many EARSS participants. We thank Dr Nico Nagelkerke for his statistical advice. The EARSS is funded by the European Commission under SI2.324194 (2001CVG4-011) and the Dutch Ministry of Health, Welfare and Sports. This work was performed at the National Institute for Public Health and the Environment, Bilthoven, The Netherlands.",

year = "2004",

month = dec,

doi = "10.1093/jac/dkh458",

language = "English",

volume = "54",

pages = "1045--1050",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "6",

}

Bruinsma, N, Kristinsson, KG, Bronzwaer, S, Schrijnemakers, P, Degener, J, Tiemersma, E, Hryniewicz, W, Monen, J, Grundmann, H, Mittermayer, H, Koller, W, Goossens, H, Hendrickx, E, Markova, B, Kalenic, S, Tambic-Andrasevic, A, Urbaskova, P, Monnet, D, Naaber, P, Lyytikäinen, O, Nissinen, A, Aubry-Damon, H, Courvalin, P, Buchholz, U, Witte, W, Legakis, N, Vatopoulos, G, Füzi, M, O'Flanagan, D, Murphy, O, Raz, R, Edelstein, H, Cornaglia, G, D'Ancona, P, Hemmer, R, Borg, M, de Neeling, A, Hoiby, A, Bjørløw, E, Caniça, M, Codita, I, Gubina, M, Kolman, J, Langsadl, L, Baquero, F, Campos, J, Liljequist, B, Johnson, A & Wale, M 2004, 'Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe', Journal of Antimicrobial Chemotherapy, vol. 54, no. 6, pp. 1045-1050. https://doi.org/10.1093/jac/dkh458

TY - JOUR

T1 - Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe

AU - Bruinsma, Nienke

AU - Kristinsson, Karl G.

AU - Bronzwaer, Stef

AU - Schrijnemakers, Paul

AU - Degener, John

AU - Tiemersma, Edine

AU - Hryniewicz, Waleria

AU - Monen, Jos

AU - Grundmann, Hajo

AU - Mittermayer, H.

AU - Koller, W.

AU - Goossens, H.

AU - Hendrickx, E.

AU - Markova, B.

AU - Kalenic, S.

AU - Tambic-Andrasevic, A.

AU - Urbaskova, P.

AU - Monnet, D.

AU - Naaber, P.

AU - Lyytikäinen, O.

AU - Nissinen, A.

AU - Aubry-Damon, H.

AU - Courvalin, P.

AU - Buchholz, U.

AU - Witte, W.

AU - Legakis, N.

AU - Vatopoulos, G.

AU - Füzi, M.

AU - O'Flanagan, D.

AU - Murphy, O.

AU - Raz, R.

AU - Edelstein, H.

AU - Cornaglia, G.

AU - D'Ancona, P.

AU - Hemmer, R.

AU - Borg, M.

AU - de Neeling, A.

AU - Hoiby, A.

AU - Bjørløw, E.

AU - Caniça, M.

AU - Codita, I.

AU - Gubina, M.

AU - Kolman, J.

AU - Langsadl, L.

AU - Baquero, F.

AU - Campos, J.

AU - Liljequist, B.

AU - Johnson, A.

AU - Wale, M.

N1 - Funding Information: We gratefully thank all national representatives, data managers and the EARSS advisory board for contributing to the success of the network during the past 5 years. We are indebted to all EARSS participants for allowing us to use their data for the present study. The EARSS national representatives for 2002 were H. Mittermayer, W. Koller (Austria), H. Goossens, E. Hendrickx (Belgium), B. Markova (Bulgaria), S. Kalenic, A. Tambic-Andrasevic (Croatia), P. Urbaskova (Czech Republic), D. Monnet (Denmark), P. Naaber (Estonia), O. Lyytikäinen, A. Nissinen (Finland), H. Aubry-Damon, P. Courvalin (France), U. Buchholz, W. Witte (Germany), N. Legakis, G. Vatopoulos (Greece), M. Füzi (Hungary), K. Kristinsson (Iceland), D. O’Flanagan, O. Murphy (Ireland), R. Raz, H. Edelstein (Israel), G. Cornaglia, P. D’Ancona (Italy), R. Hemmer (Luxembourg), M. Borg (Malta), A. de Neeling, E. Tiemersma (The Netherlands), A. Hoiby, E. Bjørløw (Norway), W. Hryniewicz (Poland), M. Canic¸a (Portugal), I. Codita (Romania), M. Gubina, J. Kolman (Slovenia), L. Langsadl (Slovakia), F. Baquero, J. Campos (Spain), B. Liljequist (Sweden), A. Johnson, M. Wale (UK). We thank John Stelling for designing and maintaining the WHONET data-entering program, which is used by many EARSS participants. We thank Dr Nico Nagelkerke for his statistical advice. The EARSS is funded by the European Commission under SI2.324194 (2001CVG4-011) and the Dutch Ministry of Health, Welfare and Sports. This work was performed at the National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

PY - 2004/12

Y1 - 2004/12

N2 - Objectives: To forecast trends in resistance to penicillin and erythromycin among Streptococcus pneumoniae in Europe. Methods: Since 1999, the European Antimicrobial Resistance Surveillance System (EARSS) has collected routine antimicrobial susceptibility test results of S. pneumoniae. To observe and predict changes of reduced susceptibility over time, we used a multinomial logistic regression model. Results: Large variations in penicillin and erythromycin non-susceptibility were observed between countries, and reduced susceptibility to erythromycin (17%) has become more frequent than reduced susceptibility to penicillin (10%) in Europe overall. An overall decrease in single penicillin non-susceptibility, but an increase in dual non-susceptibility was observed, indicating a shift of single penicillin to combined non-susceptibility with erythromycin. By 2006, the proportion of single erythromycin and dual non-susceptibility could increase to as much as 20.4% and 8.9%, respectively. Conclusions: Our results indicate that appropriately dosed β-lactams for empirical therapy are still the treatment of choice, and that macrolides should be used with prudence.

AB - Objectives: To forecast trends in resistance to penicillin and erythromycin among Streptococcus pneumoniae in Europe. Methods: Since 1999, the European Antimicrobial Resistance Surveillance System (EARSS) has collected routine antimicrobial susceptibility test results of S. pneumoniae. To observe and predict changes of reduced susceptibility over time, we used a multinomial logistic regression model. Results: Large variations in penicillin and erythromycin non-susceptibility were observed between countries, and reduced susceptibility to erythromycin (17%) has become more frequent than reduced susceptibility to penicillin (10%) in Europe overall. An overall decrease in single penicillin non-susceptibility, but an increase in dual non-susceptibility was observed, indicating a shift of single penicillin to combined non-susceptibility with erythromycin. By 2006, the proportion of single erythromycin and dual non-susceptibility could increase to as much as 20.4% and 8.9%, respectively. Conclusions: Our results indicate that appropriately dosed β-lactams for empirical therapy are still the treatment of choice, and that macrolides should be used with prudence.

KW - Antimacrobial use

KW - Antimicrobial resistance

KW - Public health

UR - http://www.scopus.com/inward/record.url?scp=19944431669&partnerID=8YFLogxK

U2 - 10.1093/jac/dkh458

DO - 10.1093/jac/dkh458

M3 - Article

C2 - 15531598

AN - SCOPUS:19944431669

SN - 0305-7453

VL - 54

SP - 1045

EP - 1050

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 6

ER -

Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this